Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | — |
No additional AE/No PQC reported.; Caller noted that she had received a pneumococcal vaccine back in the 1960's and also received PNEUMOVAX-23 on 05/26/2023; This spontaneous report was received from a Consumer or other non health professional referring to himself, a male patient of unknown age (discrepancy, also reported as a "she"). The patient's medical history was not reported. The patient's concurrent conditions were not reported. Historical drugs included Pneumococcal vaccine (unspecified). Concomitant therapies were not reported. On 26-May-2023, the patient started therapy with Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23), Solution for injection (formulation, exact dose, anatomical location, route of administration, lot # and expiration date were not reported) as prophylaxis. The patient noted that he/she had received a pneumococcal vaccine back in the 1960's (extra dose administered). No additional adverse event. The action taken with Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) was reported as not applicable. The outcome was unknown. Causality was not reported.